Legal & General Group
PTCT icon

Legal & General Group’s PTC Therapeutics PTCT Stock Holding History

Legal & General Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8M Buy
352,734
+9,354
+3% +$675K 0.01% 759
2026
Q1 		$23.4M Sell
343,380
-22,885
-6% -$1.62M 0.01% 772
2025
Q4 		$27.8M Buy
366,265
+124,923
+52% +$9.08M 0.01% 747
2025
Q3 		$14.8M Buy
241,342
+18,505
+8% +$964K ﹤0.01% 1000
2025
Q2 		$10.9M Buy
222,837
+29,993
+16% +$1.42M ﹤0.01% 1136
2025
Q1 		$9.83M Buy
192,844
+112,216
+139% +$5.6M ﹤0.01% 1144
2024
Q4 		$3.64M Buy
80,628
+1,923
+2% +$82.3K ﹤0.01% 1731
2024
Q3 		$2.92M Buy
78,705
+2,439
+3% +$81.7K ﹤0.01% 1819
2024
Q2 		$2.33M Buy
76,266
+4,368
+6% +$142K ﹤0.01% 1874
2024
Q1 		$2.09M Sell
71,898
-16,449
-19% -$461K ﹤0.01% 1921
2023
Q4 		$2.43M Sell
88,347
-12,323
-12% -$282K ﹤0.01% 1852
2023
Q3 		$2.26M Buy
100,670
+2,127
+2% +$79.1K ﹤0.01% 1848
2023
Q2 		$4.01M Sell
98,543
-10,838
-10% -$530K ﹤0.01% 1589
2023
Q1 		$5.3M Buy
109,381
+23,540
+27% +$1.08M ﹤0.01% 1384
2022
Q4 		$3.28M Buy
85,841
+5,263
+7% +$219K ﹤0.01% 1634
2022
Q3 		$4.04M Sell
80,578
-9,972
-11% -$489K ﹤0.01% 1467
2022
Q2 		$3.63M Sell
90,550
-761
-0.8% -$26.7K ﹤0.01% 1585
2022
Q1 		$3.41M Buy
91,311
+6,310
+7% +$243K ﹤0.01% 1737
2021
Q4 		$3.38M Sell
85,001
-513
-0.6% -$19.6K ﹤0.01% 1786
2021
Q3 		$3.18M Buy
85,514
+40,344
+89% +$1.66M ﹤0.01% 1782
2021
Q2 		$1.91M Buy
45,170
+7,381
+20% +$316K ﹤0.01% 1992
2021
Q1 		$1.79M Sell
37,789
-2,528
-6% -$150K ﹤0.01% 2025
2020
Q4 		$2.46M Buy
40,317
+6,170
+18% +$364K ﹤0.01% 1802
2020
Q3 		$1.6M Sell
34,147
-14,250
-29% -$702K ﹤0.01% 1861
2020
Q2 		$2.46M Buy
48,397
+6,803
+16% +$334K ﹤0.01% 1646
2020
Q1 		$1.87M Buy
41,594
+1,940
+5% +$97.7K ﹤0.01% 1617
2019
Q4 		$1.9M Buy
39,654
+4,506
+13% +$191K ﹤0.01% 1825
2019
Q3 		$1.19M Buy
35,148
+201
+0.6% +$8.75K ﹤0.01% 1920
2019
Q2 		$1.57M Sell
34,947
-29,916
-46% -$1.18M ﹤0.01% 1798
2019
Q1 		$2.44M Buy
64,863
+51,059
+370% +$1.71M ﹤0.01% 1602
2018
Q4 		$473K Buy
13,804
+2,079
+18% +$74.8K ﹤0.01% 2126
2018
Q3 		$550K Buy
11,725
+818
+7% +$33.8K ﹤0.01% 2117
2018
Q2 		$368K Sell
10,907
-527
-5% -$16.4K ﹤0.01% 2174
2018
Q1 		$309K Buy
11,434
+1,481
+15% +$37.5K ﹤0.01% 2222
2017
Q4 		$166K Buy
9,953
+539
+6% +$9.12K ﹤0.01% 2394
2017
Q3 		$186K Buy
9,414
+1,302
+16% +$25.5K ﹤0.01% 2366
2017
Q2 		$149K Hold
8,112
– – ﹤0.01% 2413
2017
Q1 		$78K Sell
8,112
-474
-6% -$5.74K ﹤0.01% 2681
2016
Q4 		$95K Buy
8,586
+3,250
+61% +$34.1K ﹤0.01% 2597
2016
Q3 		$64K Sell
5,336
-2,840
-35% -$23.1K ﹤0.01% 2408
2016
Q2 		$58K Hold
8,176
– – ﹤0.01% 2397
2016
Q1 		$52K Buy
8,176
+1,454
+22% +$25.2K ﹤0.01% 2396
2015
Q4 		$216K Hold
6,722
– – ﹤0.01% 1712
2015
Q3 		$174K Hold
6,722
– – ﹤0.01% 1767
2015
Q2 		$324K Buy
6,722
+2,465
+58% +$144K ﹤0.01% 1511
2015
Q1 		$270K Buy
4,257
+874
+26% +$53.3K ﹤0.01% 1548
2014
Q4 		$182K Hold
3,383
– – ﹤0.01% 1618
2014
Q3 		$149K Buy
+3,383
New +$106K ﹤0.01% 1651

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Legal & General Group's PTCT Position: Q2 2026 in Review

Legal & General Group increased its PTC Therapeutics (PTCT) stake by 2.7% in Q2 2026, buying an estimated $675K and bringing the position to 352,734 shares worth $28.8M. The position accounts for 0.01% of the portfolio, ranked #759.

Legal & General Group first reported a position in PTCT in Q3 2014 and has held it in 48 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Legal & General Group held 352,734 shares of PTC Therapeutics worth $28.8M as of Q2 2026.
  • Legal & General Group bought 9,354 PTC Therapeutics shares in Q2 2026, an estimated $675K.
  • PTC Therapeutics made up 0.01% of Legal & General Group's portfolio in Q2 2026, its #759 holding.
  • Legal & General Group first reported a position in PTC Therapeutics in Q3 2014 and has held it in 48 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.